Pfizer Corporation

Icagen, Inc.

Ziarco Pharma Ltd.

Ziarco Inc.

Nigel Alan Swain

David James Rawson

Robert Ian Storer

Brian Edward Marron

Alan Daniel Brown

David Simon Millan

Christopher John Markworth

Paul Anthony Stupple

Shulan Zhou

Andrew Simon Bell

Matthew Duncan Selby

Christopher William West

Serge Beaudoin

Russell Andrew Lewthwaite

Charles Eric Mowbray

Michael Christopher Laufersweiler

Steven Michael Reister

Marcel John De Groot

Kosuke Sasaki

Ian Roger Marsh

Paul Christopher Fritch

Andrew Thomas Maynard

Nunzio Sciammetta

Manuel Perez Pacheco

Thomas Ryckmans

Robert McKenzie Owen

Steven Matthieu Gaulier

Manuel Perez-Pacheco

Benjamin Scott Greener

Charlotte Alice Lane

David Howard Williams

Sebastien Rene Galan

Charlotte Alice Louise Lane

The invention relates to new sulfonamide Nav1.7 inhibitors and pharmaceutically acceptable salts thereof, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.

Sulfonamide compounds

The invention relates to sulfonamide derivatives, to their use in medicine, to 5 compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new sulfonamide Nav1.7 inhibitors of formula (I): 10 X NH O S O O R1 R2 R5 R4 R3 Het1 (I) or a pharmaceutically acceptable salt thereof, wherein X, Het1, R1, R2, R3, R4 and R5 are as defined in the description. 15 Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.

Acyl sulfonamide compounds

The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new sulfonamide Nav1.7 inhibitors of formula (I): or a pharmaceutically acceptable salt thereof, wherein X, Ar, R, R, R, Rand Rare as defined in the description. Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.

The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to new sulfonamide Nav1.7 inhibitors of formula (I) or pharmaceutically acceptable salts thereof, wherein X, Y, Y, Z, R, Rand Rare as defined in the description. Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain. 

N-sulfonylbenzamide compounds

The present invention relates to sulfonamide derivatives, of formula (I): or a pharmaceutically acceptable salts thereof, wherein X, Z, R, R, R, R, Rand Rare as defined in the description, and to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. The compounds of formula (I) are Nav1.7 inhibitors useful in the treatment of a wide range of disorders, particularly pain.

Sulfonamide derivatives

The present invention relates to new sulfonamide URAT-1 inhibitor compounds of formula (I) or a pharmaceutically acceptable salt thereof: to compositions containing them, to processes for their preparation and to intermediates used in such processes, and to methods of treatment, wherein R, R, R, R, Rand Rare as defined in the description.

Chemical compounds

The present invention relates to compounds of the formula and pharmaceutically acceptable salts, solvates or tautomers thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds, and the uses of such compounds, in particular for the treatment of pain.

The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to new sulfonamide Nav1.7 inhibitors of formula (I): or pharmaceutically acceptable salts thereof, wherein Z, R, R, R, R, R, Rand Rare as defined in the description. Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.

The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new sulfonamide Nav1.7 inhibitors of formula 10 (I):(I) or a pharmaceutically acceptable salt thereof, wherein Z, R1, R2, R3, R4 and R5 are as defined in the description. Nav1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.

The invention is directed to compounds of Formula I in which:R, R, B and Z are defined supra.

Inhibitors of ion channels

The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new sulfonamide Nav1.7 inhibitors of formula (I): or a pharmaceutically acceptable salt thereof, wherein Ar, X, R, R, R, Rand Rare as defined in the description. Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.

This invention relates to sulfonamide derivative of formula (I), to their use in medicine, to compositions containing them, to processes for their preparation, and to intermediates used in such processes.  These compounds are inhibitors of Nav1.7.

Sulfonamide derivatives as Nav 1.7 inhibitors

The invention is directed to compounds of the formula in which R,B and Z are defined supra.

Growing community of inventors

Sandwich, United Kingdom

Nigel Alan Swain